Post by Cambridge Biocapital

#79 The Newsletter | GSK agrees to acquire Nuvalent for $10.6bn. THENA Capital closes £45m debut fund. MHRA clears Oxford-Moderna mRNA vaccine trial to prevent Lynch syndrome cancers. Read the full edition here: https://lnkd.in/eGPJD49Q Featured in this week's edition: Impli, Adamo Foods, Harness Therapeutics, THENA Capital, Creator Fund, Playground Global, British Business Bank, Midlands Mindforge, Midlands Innovation, University of Oxford, Reacta Healthcare, bit.bio, Epoch Biodesign, Pangea Bio, MitoRx Therapeutics, Cytospire Therapeutics Ltd, LivaNova, Wellcome Sanger Institute, Google DeepMind, Engitix Therapeutics, GSK, Amphista Therapeutics Limited, PhoreMost Ltd, CellVoyant, Axol Bioscience Ltd., Fleming Initiative, OpenFold, Kiin Bio, Nxera Pharma, HutanBio, Laverock Therapeutics, AstraZeneca, Silence Therapeutics plc